SCHEMBL7082292

SCHEMBL7082292

Cc1ccnc(C(=O)CC(=O)c2ccc(OCc3ccc(F)cc3)s2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
KDM5A P29375 3/20 0.37
KDM5B Q9UGL1 3/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
TP53 P04637 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
KDM4C Q9H3R0 2/20 0.37
BRD4 O60885 1/20 0.36
NOX1 Q9Y5S8 1/20 0.36
PIK3CA P42336 1/20 0.36
AGTR1 P30556 1/20 0.36
ATM Q13315 1/20 0.36
AKT3 Q9Y243 1/20 0.36
MAOB P27338 4/20 0.35
MAOA P21397 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7077348 0.84 AGTR1 (0.47) CNR1CNR2RAB9ASMN1; SMN2MEN1
SCHEMBL7826615 0.76 ERCC5 (0.48) RAB9AMEN1KMT2AMAOBMAPT
SCHEMBL7081312 0.74 MAOB (0.54) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL7078399 0.71 RAB9A (0.40) NPC1RAB9ATP53SMN1; SMN2MEN1
SCHEMBL7078553 0.70 CNR2 (0.53) CNR1CNR2NPC1RAB9ATP53
SCHEMBL7078408 0.68 SMN1; SMN2 (0.41) NPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL8278886 0.67 LMNA (0.45) KDM5AKDM5BNPC1RAB9ASMN1; SMN2
SCHEMBL31312593 0.67 ALDH1A1 (0.42) NPC1RAB9ATP53SMN1; SMN2MAPT
SCHEMBL15926105 0.66 CTSA (0.43) NPC1RAB9ATP53SMN1; SMN2MEN1
SCHEMBL7817640 0.66 ERCC5 (0.46) KDM5AKDM5BKDM4CMAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof PAYNE LINDA S (US) 2003-12-11 US claimed
EP-1196384-A4 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO INC (US) 2002-10-23 EP claimed
EP-1196384-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF Merck & Co., Inc. (US) 2002-04-17 EP claimed
WO-2001000578-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO., INC. (US) 2001-01-04 WO claimed
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof PAYNE LINDA S (US) 2003-12-11 US disclosed
EP-1196384-A4 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO INC (US) 2002-10-23 EP disclosed
EP-1196384-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF Merck & Co., Inc. (US) 2002-04-17 EP disclosed
WO-2001000578-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO., INC. (US) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof CYP2S1, IMPDH1, IDO1 CNR1 3011/4885CNR2 4088/4885KDM5A 2332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.